Usage: Melt on the tongue or dissolve in a glass of water (100 ml)
While the manufacturer is on the list of authorized GLP-1 importers, FDA inspectors found the company relabeled APIs from another site in a potential attempt to circumvent safeguards. A Chinese company has fallen afoul of the FDAs recently introduced restrictions on GLP-1 receptor agonist imports, leading the agency to issue a warning letter over semaglutide shipments
More than 74% of diabetic patients are classified under type 2 diabetes, where GLP-1 therapies demonstrate high clinical effectiveness
If NASH worsens, it can lead to severe liver scarring (cirrhosis) and even liver cancer
#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts